<DOC>
	<DOCNO>NCT02306291</DOCNO>
	<brief_summary>This study evaluate GMI-1271 , specific E-selectin antagonist , acute myeloid leukemia combination standard agent use treat disease .</brief_summary>
	<brief_title>Study Determine Safety , Pharmacokinetics Efficacy GMI-1271 Combination With Chemotherapy AML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Inclusion criterion : 1 . AML ( include secondary AML ) diagnose per WHO criteria 2 . For relapsed/refractory subject : Subjects age ≥ 18 year relapse refractory AML ≤ 2 prior induction regimen , least one contain anthracyclines Medically eligible receive MEC Absolute blast count ( ABC ) ≤ 40,000/mm 3 . For treatmentnaïve subject : Subjects ≥ 60 year age newly diagnose AML Medically eligible receive `` 7+3 '' cytarabine/idarubicin ABC count ≤ 40,000/mm 4 . ECOG performance status 02 5 . Hemodynamically stable adequate organ function Exclusion criterion : 1 . Acute promyelocytic leukemia 2 . Acute leukemia ambiguous lineage ( biphenotypic leukemia ) 3 . Active sign symptom CNS involvement malignancy 4 . No prior GCSF , GMCSF plerixafor within 14 day study drug dose 5 . Known history evidence active hepatitis A , B , C HIV 6 . Uncontrolled acute life threaten bacterial , viral fungal infection 7 . Active graft versus host disease ( GVHD ) ≥ Grade 2 extensive chronic GVHD require immunosuppressive therapy 8 . Hematopoietic stem cell transplantation ≤ 4 month dose 9 . Clinically significant cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>E-selectin</keyword>
	<keyword>relapse refractory</keyword>
	<keyword>elderly newly diagnose</keyword>
	<keyword>induction</keyword>
</DOC>